What should work, may not.
When new agents such as bortezomib appear, it is important to maintain scientific rigor regarding off-label use of medications.
Kirk
A D
AD
D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D017277:Drug Approval; D004348:Drug Labeling; D011307:Drug Prescriptions; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D056687:Off-Label Use; D016377:Organ Transplantation / Q000379:methods*; D011719:Pyrazines / Q000627:therapeutic use; D012107:Research Design; D014481:United States; D014486:United States Food and Drug Administration
D001897:Boronic Acids; D007166:Immunosuppressive Agents; D011719:Pyrazines; D000069286:Bortezomib